

# Resource Summary Report

Generated by [PRECISE-TBI](#) on Aug 1, 2026

## B6.Cg-Xcr1<sup>tm2</sup>(HBEGF/Venus)Ksho

RRID:IMSR\_RBRC09485

Type: Organism

### Proper Citation

RRID:IMSR\_RBRC09485

### Organism Information

**URL:** <https://brc.riken.jp/mus/RBRC09485>

**Proper Citation:** RRID:IMSR\_RBRC09485

**Description:** Mus musculus with name B6.Cg-Xcr1<sup>tm2</sup>(HBEGF/Venus)Ksho from IMSR.

**Species:** Mus musculus

**Notes:** gene symbol note: chemokine (C motif) receptor 1; mutant strain: Xcr1

**Affected Gene:** chemokine (C motif) receptor 1

**Genomic Alteration:** targeted mutation 2; Tsuneyasu Kaisho

**Catalog Number:** RBRC09485

**Database:** RIKEN BioResource Research Center

**Database Abbreviation:** RBRC

**Availability:** embryo

**Organism Name:** B6.Cg-Xcr1<sup>tm2</sup>(HBEGF/Venus)Ksho

**Record Creation Time:** 20250513T061514+0000

**Record Last Update:** 20260801T054955+0000

### Ratings and Alerts

No rating or validation information has been found for B6.Cg-Xcr1<sup>tm2</sup>(HBEGF/Venus)Ksho.

No alerts have been found for B6.Cg-Xcr1<sup>tm2</sup>(HBEGF/Venus)Ksho.

---

## Data and Source Information

**Source:** [Integrated Animals](#)

**Source Database:** RIKEN BioResource Research Center

---

## Usage and Citation Metrics

We found 4 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [PRECISE-TBI](#) .

Meiser P, et al. (2023) A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity. *Cancer cell*, 41(8), 1498.

de Mingo Pulido Á, et al. (2021) The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake. *Immunity*, 54(6), 1154.

Flommersfeld S, et al. (2021) Fate mapping of single NK cells identifies a type 1 innate lymphoid-like lineage that bridges innate and adaptive recognition of viral infection. *Immunity*, 54(10), 2288.

Tsuchiya N, et al. (2019) Type I Interferon Delivery by iPSC-Derived Myeloid Cells Elicits Antitumor Immunity via XCR1+ Dendritic Cells. *Cell reports*, 29(1), 162.